207_Combined course Presentations
Basket trials matching patients to therapies based on molecular profiles
Primary outcome measure(s)
rogram ame
Lead organization
# Expected to accrue
Clinicaltrials.go v identifier
Design
Histology Indication
PI3K-activated solid tumors and/or hematologic malignancies BRAF V600 - mutated solid tumors and/or hematologic malignancies
IGNATURE
Novartis
NR
Metastatic
145
CBR
NCT01833169
Metastatic
12
CBR
NCT01981187
PTCH1 or SMO mutated
Metastatic
10
CBR
NCT02002689
RAS/RAF/MEK activated
Metastatic
110
CBR
NCT01885195
CDK4/6 pathway activated
Metastatic
90
CBR
NCT02187783
FGFR mutated Metastatic
70
CBR
NCT02160041
Made with FlippingBook